GFGY yields 0.05% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, GFGY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GFGY + ABBV for your $10,000?
Granite Falls Energy, LLC, together with its subsidiaries, engages in the production and sale of ethanol and its co-products in the continental United States. The company offers wet, modified wet and dried distillers' grains, corn oil, and corn syrup. Its ethanol is a fuel component for the wholesale gasoline distributors or blenders, which is produced from corn and various other grains for use as an octane enhancer in fuels; an oxygenated fuel additive for reducing ozone and carbon monoxide vehicle emissions; a non-petroleum-based gasoline substitute; and a renewable fuel to displace consumption of imported oil. The company also provides distillers grains, a co-product of the ethanol production process that is used as an animal feed ingredient in the beef and dairy industries; corn oil, which is used primarily as a biodiesel feedstock and as a supplement for animal feed; and corn syrup, a by-product of the ethanol production process. In addition, it operates 190 miles of natural gas pipeline. The company markets and distributes its ethanol and distillers' grains through its third-party marketers; and sells corn oil to diesel manufacturers. In addition, it exports its products. Granite Falls Energy, LLC was incorporated in 2000 and is headquartered in Granite Falls, Minnesota.
Full GFGY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.